Why Payment Processors Drop Peptide and GLP-1 Offers — and What Survives Underwriting

Why do Stripe and PayPal terminate peptide sellers?

Stripe and PayPal terminate peptide sellers because the underlying product still reads as an unapproved drug under federal law, and that risk transfers directly into the processor's own agreement with its acquiring bank. FDA's March 31, 2026 warning letter to Gram Peptides found that "Research Use Only" and "not intended for human consumption" language on the label did not matter once the company's website carried mechanism-of-action and weight-loss copy — evidence of intended use, per the standard set out in 21 CFR 201.128. Processors read the same landing pages FDA reads.

The same letter found that selling bacteriostatic water alongside peptides needing reconstitution independently proved human-use intent, since FDA reasoned the pairing showed the water was meant "to be used in combination for injection." A merchant account underwriter sees the identical signal: a checkout page bundling a peptide vial with mixing water looks like an injection kit, not a research sample, and that bundle alone can trigger termination for cause well before any chargeback pattern develops.

State enforcement adds a second data point processors now scan for. Alabama's attorney general shut down Aurora IV and Wellness in November 2025 for injecting patients with material labeled for laboratory research only, and Connecticut's attorney general extracted an $18,500 settlement from a raw-powder distributor the same year. Neither case involved a payment dispute — both involved regulators, which is precisely the kind of exposure a payment facilitator has no appetite to inherit. For the marketing-copy side of that exposure, see peptide advertising rules.

How do card networks classify peptides and unapproved drugs?

Card networks classify a peptide merchant the way FDA already classified the product, not the way the merchant's landing page describes it. Under the FD&C Act's standard enforcement chain, a product intended to treat, mitigate or affect the structure of the body qualifies as a drug under section 201(g)(1), and because none of these peptides has completed the approval process, it becomes an unapproved "new drug" under section 201(p) — the same chain FDA cited against Gram Peptides. Acquiring banks that board a merchant selling an unapproved new drug carry that same regulatory exposure.

Synthetic peptides can't hide inside the dietary supplement category either. Section 321(ff)(1) defines a dietary supplement as a closed list — vitamins, minerals, herbs, amino acids and similar dietary substances — and a synthetic non-food peptide such as BPC-157 does not fit any branch of that list. Food-derived ingredients like hydrolyzed collagen do fit, which is the underwriting line that actually separates a "supplement" processor from a "drug" decline.

BPC-157's regulatory status shifted twice in one year without becoming compoundable. FDA withdrew its Category 2 listing on April 22, 2026 at the nominator's request — a procedural move, not a safety clearance — and BPC-157 still fails all three qualifying paths for lawful 503A compounding: no USP monograph, no FDA-approved-drug component status, and no bulks-list entry. A card network's risk team treats that kind of unresolved listing status as a live flag, not a closed question.

The exact merchant category code an acquirer assigns to a peptide seller varies by processor and is not something the networks publish as a single fixed table, so treat any specific MCC number circulating among media buyers as a starting point to confirm with your own acquirer, not a rule.

What is the MATCH list and how do sellers end up on it?

The MATCH list — Mastercard's Alert to Control High-risk Merchants file — is a shared database acquirers check before boarding any new merchant account, and a listing typically follows termination for cause rather than a routine decline. Reason codes cover fraud, money laundering and excessive chargebacks, but an unresolved FDA warning letter or a state attorney general action can also justify termination for cause when an acquirer's compliance team reviews the file.

The five-year retention period commonly quoted among nutra operators needs checking against Mastercard's current member rules directly with your acquirer before you plan around it — it is the figure buyers repeat, not a number confirmed here. What is consistent is the downstream effect: once listed, the operator's next several processor applications tend to get auto-declined at the acquirer's initial risk screen, before a human underwriter ever reads the offer copy.

A listing attaches to the business and its principals, not just the storefront, which is why operators who cycle through new LLCs after a termination often get caught anyway — the MATCH check runs against ownership details, not brand names alone.

How does LegitScript merchant monitoring feed processor decisions?

LegitScript merchant monitoring feeds processor decisions because most high-risk acquirers rely on the same verification layer that Meta and Google already require for pharmacy and telehealth advertisers, so a flag in one system tends to surface in the other. Meta requires online pharmacies and telehealth providers to hold active LegitScript certification before it will even review a prescription-drug ad, and Google requires LegitScript Healthcare Merchant Certification or NABP accreditation for the same category in US-targeted campaigns.

LegitScript's monitoring is continuous, not a one-time credential. Most operators treat certification as the finish line; it is closer to a checkpoint. A merchant can hold an active LegitScript certificate and still lose a processor relationship the week an FDA warning letter names a supplier or a landing page drifts into an implied disease claim, because certification verifies documented pharmacy licensing and business legitimacy — it does not measure federal drug-classification risk, and FDA's intended-use doctrine operates independently of any certificate on file.

The claim structure matters more than the certificate. FDA's own disease-claim rule treats naming a prescription drug inside supplement labeling as evidence of an implied disease claim, and "for Ozempic users" or "eases GLP-1 side effects" positioning sits squarely inside that trap regardless of what license sits on file with LegitScript.

What happens to held funds when an account is terminated?

When a card network terminates a peptide merchant for cause, the funds usually enter a reserve rather than disappearing outright, and the terms of that reserve sit in the merchant agreement the operator signed and rarely read closely. Acquirers commonly cite hold periods in the 90-to-180-day range and rolling reserves in the 10-to-20-percent range for terminated high-risk merchants — treat both as figures repeated across the industry rather than confirmed processor policy, and check the exact numbers in your own agreement before assuming either applies.

Chargebacks keep posting against the reserve during the hold window, which is why the released balance at the end often runs lower than the operator expects. If a state attorney general action or an FTC substantiation inquiry — measured against FTC's "competent and reliable scientific evidence" standard — surfaces while the account sits in reserve, the acquirer can extend the hold rather than release it on schedule.

The fund hold and the MATCH listing are separate consequences of the same termination event, and resolving one does nothing to resolve the other; an operator can wait out a reserve period in full and still find every new processor application declined on the file check.

Can GLP-1 support supplements get standard processing?

Standard processing stays available to GLP-1 support supplements only when the offer avoids naming the prescription drug and avoids disease-level claims, and most "GLP-1 support" copy fails one test or the other. FDA's disease-claim rule treats naming a prescription drug inside supplement labeling as evidence of an implied drug claim, and FTC's Gut Check guidance separately lists specific weight-loss claims — like substantial loss "no matter what or how much the consumer eats" — that its own experts say cannot be true of any product.

The ingredient class is the underwriting line that actually holds. Hydrolyzed collagen peptides and whey protein hydrolysates qualify as lawful dietary substances because they were marketed as food long before any drug investigation began, while synthetic research peptides fall outside that protection entirely — a distinction most "peptide-friendly" landing pages ignore because it doesn't sell as well as a mechanism-of-action claim does. For what that category actually looks like today, see compliant plays for the peptide boom.

Symptom-support positioning built around electrolytes, fiber and nausea relief sits closer to standard-risk processing than anything built around the injectable itself, provided the copy never names the drug or implies equivalence to it. That is the specific category covered in offers targeting GLP-1 users, and it is also the category where Meta's ban on second-person health copy — phrasing like "your diabetes" instead of a category reference — does the most damage to a careless media buyer's account.

What underwriting questions predict whether an offer survives?

The questions that predict survival are structural, not creative: what is the ingredient, what does the claim name, how is it bundled at checkout, and who legally owns the clinic. An underwriter working a peptide or GLP-1 file runs through those four questions before reading a single piece of ad copy, because each one maps to a specific enforcement pattern regulators have already used.

Clinic ownership is the fastest-moving line in that list. Oregon's SB 951, signed June 9, 2025, bars management services organizations from majority ownership or de facto clinical control of new arrangements starting January 1, 2026, and California's SB 351, effective the same date, bars private equity managers of physician practices from controlling clinical decisions. An underwriter reading a corporate structure that predates those laws is reading a liability the operator may not have priced in yet.

Documentation discipline is the one factor an operator controls directly. Consistent account and campaign naming across a portfolio gives an underwriter a clean audit trail instead of a pile of ad-hoc account names that look like structuring, a discipline covered in a naming convention that survives 40 nutra offers.

None of that replaces knowing what is actually live in the category before you build an underwriting file around it, which is the gap peptide affiliate offers running in 2026 is built to close. The operators who survive underwriting are the ones who treated the offer's legal shape as the product, not the landing page.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

When the topic touches health claims, platform policy, or GLP-1 market research, validate the observable campaign signals against primary references such as FDA human drug compounding, FTC health claims guidance, and Meta advertising standards. Daily Intel adds the proprietary direct-response layer by mapping how those rules show up in active VSLs, Meta creatives, funnels, transcripts, UTMs, and checkout paths.

For deeper evaluation, continue through Nutra niche intelligence directory, Methylene Blue Offers: A Biohacker Ad Wave Decoded, TikTok Supplement Ads: What Scales and What's Banned, Peptides vs. DSHEA: Why Most Peptides Can Never Be Supplements, Why 'Research Use Only' Is Not a Legal Shield for Peptide Sellers, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.